Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)

Part of paid clinical trials in Pleasanton, California.

Sponsor
Weill Medical College of Cornell University
Study ID
NCT07298993
Phase
PHASE4
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
60 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Placebo (matching) — DRUG
    Beta-blocker dosage will be reduced over the course of 4 weeks until the participant is completely off of beta-blocker and transitioned to matching placebo capsules.
  • Beta-blockers — DRUG
    Participants will continue their pre-enrollment beta-blocker at the same dose. The beta-blocker agent may include atenolol, bisoprolol, carvedilol, metoprolol succinate, or metoprolol tartrate. Medication will be provided in matching capsules to maintain blinding.

Study Details

The goal of this study is to learn whether stopping beta-blockers can help older adults with heart failure with preserved ejection fraction (HFpEF) feel better and function better. This study will test whether "deprescribing" or stopping these medications in a careful, guided way can improve symptoms and quality of life. Participants will be randomly assigned to one of two groups: Deprescribing group: Beta-blockers are gradually reduced using capsules that contain decreasing doses. Usual care group: Beta-blockers are continued at the usual dose in look-alike capsules. All participants will: * Take study medicine for about 4 months * Have their blood pressure and heart rate monitored * Complete regular phone calls and questionnaires about how they are feeling This study does not involve any experimental medication. Participants active involvement in the study will last approximately 4 months. During these 4 months they will have 8 scheduled telephone visits.

Key Dates

Start date
Feb 2, 2026
Status verified
Feb 2026
Primary completion
Apr 30, 2029
Completion
Apr 30, 2029

Study Design

Enrollment
240 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH

Arms

  • Placebo Comparator: Deprescribe
    Participants will have their beta-blocker replaced with pills that have decreasing amounts of beta-blocker until they are completely off their medicine and taking placebo pills.
  • Active Comparator: Continuation
    Participants will continue their beta-blocker at their usual dose in capsules that look identical to those used for the deprescribe arm.

Primary Outcome Measure

The Hierarchical Composite Endpoint [ Time Frame: From baseline (day 0) to end of the follow-up phase (day 120) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Kaiser Permanente Northern California (KPNC)PleasantonCalifornia94588-

Find similar trials in Pleasanton, CA

By condition
Heart failure
By specialty
CardiologyHeart disease
By research site
Kaiser Permanente Northern California (KPNC)· Pleasanton, CA

Related Studies